Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7450

Shown on this page

Current sort

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Colorado Anschutz

Live official records

Open in full search

Conditions: Cystic Fibrosis-related Diabetes
Interventions: iLet Bionic Pancreas System (BP), Usual Care (UC); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 14 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more

Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions: Evolocumab, Routine Lipid Management; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more

Conditions: REM Sleep Behavior Disorder
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 13 more

Conditions: Dementia, Decision Aids
Interventions: Decision aid; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Cetuximab, Computed Tomography, Echocardiography Test, Encorafenib, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Irvine, California • Los Angeles, California + 12 more

Conditions: Small Cell Lung Cancer Extensive Stage
Interventions: Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide, Rescue Medications; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Ianalumab, Eltrombopag, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: UCART22, CLLS52; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 5
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 26
States / cities: Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 22 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax, cBTKi Monotherapy; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 20
States / cities: Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more

Clinical trials in Aurora, Colorado

Filter and sort this location

Institutions in Aurora

Live official records

Bionic Pancreas in CFRD

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Decision Aid for Anti-Amyloid Therapy

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period